News

blood pressure, systolic, hypertension, younger adults, cardiovascular, risk

Younger adults with elevated systolic blood pressure have a higher risk for cardiovascular disease and coronary heart disease than those with normal blood pressure, according to a large long-...

Ostar Healthcare Technology announced the North American launch of their Cellular P201 telehealth blood pressure monitoring system. This advanced chronic disease remote monitoring system...

Millions of people take angiotensin receptor blockers (ARBs) to help treat heart failure. But it turns out not all ARBs are created equally, according to one Nova Southeastern University (NSU)...

Blood pressure monitoring, hypertension, heart failure, remote monitoring, OSTAR

Ostar Healthcare Technology, a Washington State Based TeleHealth Solutions company, announced the North American launch of Cellular TeleHealth Blood Pressure Monitoring System.

antiplatelet therapy, pharmaceuticals, cath lab, clinical trial, ticagrelor

AstraZeneca announced that the PEGASUS-TIMI 54 study, a large-scale outcomes trial involving more than 21,000...

rivaroxaban, Xarelto, safety performance, Janssen, NVAF

A new post-marketing study evaluating the safety of once-daily rivaroxaban (Xarelto) shows, in patients with non-valvular atrial fibrillation (NVAF), rates and patterns of major...

CVRx, Barostim neo Legacy System, pacemaker, hypertension, FDA, HDE

The U.S. Food and Drug Administration (FDA) has granted a humanitarian device exemption for the CVRx Inc. Barostim neo Legacy System.

More than 10 percent of patients treated with aspirin therapy for primary cardiovascular disease prevention were likely inappropriately prescribed medication, according to a new study in the...

Savaysa, Daiichi Sankyo, edoxaban, FDA, approval, NVAF, thromboembolism

Daiichi Sankyo Co. Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved Savaysa (edoxaban) tablets, an oral, once-daily selective factor Xa-inhibitor, to reduce the risk of...

Discussions regarding late-breaking cardiovascular clinical trials among leading medical scientists are placing considerable emphasis on individualized patient care, particularly in the area of...

Wearable technologies, possible changes to stenting practices, state legislation on energy drinks, expanded use of minimally invasive heart repair procedures, and the development of a new class of...

The most accessed research studies in the Journal of the American College of Cardiology (JACC) in 2014 spanned many topics, including a blood test to rule out heart attack, an advisory...

Alere, INRatio, INRatio2, PT/INR Monitor system, correction

Alere Inc. has initiated a voluntary correction to inform United States users of the Alere INRatio and INRatio 2 PT/INR Monitor system of certain medical conditions that should not be tested with...

NHLBI, Losartan, Marfan syndrome, atenolol

A National Institutes of Health-funded study comparing treatment with widely used blood pressure medications, atenolol or losartan, in patients with Marfan syndrome who had an enlarged aortic root...

AHA, warfarin, antiplatelet therapy, atrial fibrillation, anti-clotting, EP lab

Long-term overtreatment with the anti-clotting drug warfarin combined with antiplatelet therapy to prevent stroke may raise the risk of dementia in people with atrial fibrillation.

DAPT study

Patients who took dual antiplatelet therapy medications beyond the standard 12 months after coronary stent placement were significantly less likely to develop blood clots within their stents or to...

The actions — or inaction — of patients should be considered in programs designed to improve care and patient outcomes, according to a report released by the American College of Cardiology,...

Heart disease and stroke are the leading causes of death and disability among people with Type 2 diabetes. At least 65 percent of people with diabetes die from some form of heart disease or stroke...

October 15, 2014 — Novartis Pharmaceuticals Canada Inc. revealed, in the largest heart failure study to date, that its investigational heart failure medicine, LCZ696, was superior to the ACE-...

Researchers have discovered a previously unknown cardiac molecule that could provide a key to treating and preventing heart failure...